Patents by Inventor Xiaocheng Chen

Xiaocheng Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD3 antibodies and methods of use
    Patent number: 11186650
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: November 30, 2021
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Robert F. Kelley, Mary A. Mathieu, Liping L. Sun
  • Anti-CD3 antibodies and methods of use
    Patent number: 10865251
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: December 15, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Robert F. Kelley, Mary A. Mathieu, Liping L. Sun
  • EXPRESSION AND SECRETION SYSTEM
    Publication number: 20200385704
    Abstract: The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic acid molecules.
    Type: Application
    Filed: March 17, 2020
    Publication date: December 10, 2020
    Inventors: Devin TESAR, Xiaocheng CHEN, Mark DENNIS, Isidro HOTZEL
  • ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20200369746
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, Fc dimers and fusion proteins comprising such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: February 5, 2020
    Publication date: November 26, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF
    Publication number: 20200325248
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 15, 2020
    Inventors: Xiaocheng CHEN, Mark DENNIS, Janet JACKMAN, James T. KOERBER, Mason LU, Henry R. MAUN, Kathila RAJAPAKSA, Saroja RAMANUJAN, Tracy STATON, Lawren WU, Tangsheng YI
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE
    Publication number: 20200299408
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 24, 2020
    Inventors: Xiaocheng CHEN, Mark S. DENNIS, Allen J. EBENS, JR., Teemu T. JUNTTILA, Robert F. KELLEY, Mary A. MATHIEU
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE
    Publication number: 20200299409
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 24, 2020
    Inventors: Xiaocheng CHEN, Mark S. DENNIS, Allen J. EBENS, Jr., Teemu T. JUNTTILA, Robert F. KELLEY, Mary A. MATHIEU
  • Anti-tryptase antibodies, compositions thereof, and uses thereof
    Patent number: 10752703
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: August 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
  • ENGINEERED POLYPEPTIDES
    Publication number: 20200262890
    Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
    Type: Application
    Filed: September 17, 2019
    Publication date: August 20, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
  • Anti-HER2 Antibodies and Immunoconjugates
    Publication number: 20200255539
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: December 19, 2019
    Publication date: August 13, 2020
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Anti-tryptase antibodies, compositions thereof, and uses thereof
    Patent number: 10738131
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: August 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
  • ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20200223935
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 16, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • ANTI-TAU ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200216522
    Abstract: In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 9, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Lesley Ann Kane, Do Jin Kim, Joseph W. Lewcock, Suresh Poda, Rishi Rakhit, Rinkan Shukla, Adam P. Silverman
  • Anti-CLL-1 Antibodies and Methods of Use
    Publication number: 20200148774
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Application
    Filed: October 21, 2019
    Publication date: May 14, 2020
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • Anti-CD3 antibodies and methods of use
    Patent number: 10640572
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Teemu T. Junttila, Robert F. Kelley, Mary A. Mathieu
  • Workload based dynamic erase suspend adaptation
    Patent number: 10643711
    Abstract: Aspects relate to dynamically adapting the number of erase suspend operations on a non-volatile memory (NVM) based on the workload. In some aspects, erase suspend optimization involves computing a workload statistic based on at least read operations performed on the NVM over time, setting a maximum number of erase suspend operations allowed to be performed when the workload statistic compares favorably to a workload threshold, and preventing erase suspend operations from being performed when the workload statistic compares unfavorably to the workload threshold.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: May 5, 2020
    Assignee: WESTERN DIGITAL TECHNOLOGIES, INC.
    Inventors: Jingfeng Yuan, Xiaocheng Chen
  • Expression and secretion system
    Patent number: 10633650
    Abstract: The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic acid molecules.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Devin Tesar, Xiaocheng Chen, Mark Dennis, Isidro Hotzel
  • Immunoconjugates Comprising Anti-HER2 Antibodies and Pyrrolobenzodiazepines
    Publication number: 20200085840
    Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
    Type: Application
    Filed: April 23, 2019
    Publication date: March 19, 2020
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Anti-HER2 antibodies and immunoconjugates
    Patent number: 10556966
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Anti-CLL-1 antibodies and methods of use
    Patent number: 10501545
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: December 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu